JAMA Network
About The Study: In this binational study of older adults with diabetes, nearly 6 in 10 U.S. adults and 3 in 10 Japanese adults discontinued glucagon-like peptide-1 receptor agonists (GLP-1RAs) within 12 months of initiating injectable semaglutide. Patients with established cardiovascular disease and chronic kidney disease had higher discontinuation rates in both countries, which is troublesome given the substantial clinical benefit these high-risk individuals would be expected to derive from GLP-1RA therapy.
/Public Release. This material from the originating organization/author(s) might be of the point-in-time nature, and edited for clarity, style and length. Mirage.News does not take institutional positions or sides, and all views, positions, and conclusions expressed herein are solely those of the author(s).View in full here.
